AR060442A1 - Derivados cristalinos de (2-oxo-1,2,4,5-tetrahidro-1,3-benzodiazepin-3-il)piperidina - Google Patents

Derivados cristalinos de (2-oxo-1,2,4,5-tetrahidro-1,3-benzodiazepin-3-il)piperidina

Info

Publication number
AR060442A1
AR060442A1 ARP070101573A ARP070101573A AR060442A1 AR 060442 A1 AR060442 A1 AR 060442A1 AR P070101573 A ARP070101573 A AR P070101573A AR P070101573 A ARP070101573 A AR P070101573A AR 060442 A1 AR060442 A1 AR 060442A1
Authority
AR
Argentina
Prior art keywords
acid
tetrahidro
benzodiazepin
piperidine
oxo
Prior art date
Application number
ARP070101573A
Other languages
English (en)
Inventor
Gunter Huchler
Uwe Ries
Sonja Sproli
Ulrike Werthmann
Andreas Zopf
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR060442A1 publication Critical patent/AR060442A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)

Abstract

Se refiere a los nuevos compuestos cristalinos A de la formula general 1 en la que A1 significa Br, -CH3, -CF3 o -C2H5, A2 significa -NH2, -OH o -C2H5, A3 significa Br, CI, -CH3 o H, X significa -CH2-, -NH- o -O-, Y1 significa N o CH, Y2 significa N o CH e Y3 significa -CH2-, -N(CH3)- o -O-, y que se presentan en forma de sus sales con ácidos, fisiologicamente tolerables, habiéndose seleccionado los ácidos a partir del grupo B constituido por ácido clorhídrico, ácido bromhídrico, ácido sulfurico, ácido fosforico, ácido bencenosulfonico, ácido p-toluenosulfonico, ácido maleico, ácido succínico, ácido fumárico, ácido D-(-)-tartárico, ácido L-(+)-tartárico, ácido naftalin-2-sulfonico y ácido naftalin-1,5-disulfonico, así como a los polimorfos, a los correspondientes solvatos e hidratos.
ARP070101573A 2006-04-13 2007-04-13 Derivados cristalinos de (2-oxo-1,2,4,5-tetrahidro-1,3-benzodiazepin-3-il)piperidina AR060442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006017827A DE102006017827A1 (de) 2006-04-13 2006-04-13 Neue kristalline Verbindungen

Publications (1)

Publication Number Publication Date
AR060442A1 true AR060442A1 (es) 2008-06-18

Family

ID=38514672

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101573A AR060442A1 (es) 2006-04-13 2007-04-13 Derivados cristalinos de (2-oxo-1,2,4,5-tetrahidro-1,3-benzodiazepin-3-il)piperidina

Country Status (20)

Country Link
US (1) US7638625B2 (es)
EP (1) EP2010513A2 (es)
JP (1) JP2009533387A (es)
KR (1) KR20090007428A (es)
CN (1) CN101421263A (es)
AR (1) AR060442A1 (es)
AU (1) AU2007239505A1 (es)
BR (1) BRPI0710151A2 (es)
CA (1) CA2648140A1 (es)
CO (1) CO6140057A2 (es)
DE (1) DE102006017827A1 (es)
EA (1) EA200802049A1 (es)
EC (1) ECSP088737A (es)
MX (1) MX2008013158A (es)
NO (1) NO20083709L (es)
PE (1) PE20080735A1 (es)
TW (1) TW200808767A (es)
UY (1) UY30280A1 (es)
WO (1) WO2007118819A2 (es)
ZA (1) ZA200806859B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
PE20080370A1 (es) * 2006-06-08 2008-06-13 Boehringer Ingelheim Int Derivados de quinazolinona como antagonistas de cgrp
CN104136437B (zh) * 2012-02-27 2016-05-11 百时美施贵宝公司 N-(5s,6s,9r)-4-(2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-1-基)哌啶-1-羧酸5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5h-环庚三烯并[b]吡啶-9-基酯半硫酸盐

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
NO20083709L (no) 2008-10-31
CA2648140A1 (en) 2007-10-25
CO6140057A2 (es) 2010-03-19
TW200808767A (en) 2008-02-16
US20080086003A1 (en) 2008-04-10
PE20080735A1 (es) 2008-07-25
JP2009533387A (ja) 2009-09-17
WO2007118819A3 (de) 2008-05-29
EP2010513A2 (de) 2009-01-07
DE102006017827A1 (de) 2007-10-18
MX2008013158A (es) 2008-10-22
BRPI0710151A2 (pt) 2011-08-02
ECSP088737A (es) 2008-10-31
EA200802049A1 (ru) 2009-04-28
WO2007118819A2 (de) 2007-10-25
ZA200806859B (en) 2009-08-26
US7638625B2 (en) 2009-12-29
KR20090007428A (ko) 2009-01-16
UY30280A1 (es) 2007-11-30
CN101421263A (zh) 2009-04-29
AU2007239505A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
AR121612A2 (es) Inhibidores de glucosilceramida sintasa
EA201200537A1 (ru) Способ получения глюкопиранозил-замещенных производных бензилбензола
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
AR075227A1 (es) Procedimiento de sintesis de ivabradina y sus sales de adicion de acidos farmaceuticamente aceptables.
AR082499A1 (es) Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20120135A1 (es) Piperidinas sustituidas como antagonistas de ccr3
EA201200741A1 (ru) Способ получения этексилата дабигатрана
NI201000198A (es) Compuestos triazina como inhibidores mtor y quinasa p13.
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
CR7691A (es) Nuevo procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
MY152281A (en) 4-pyrimidinesulfamide derivative
DK2197860T3 (da) Nye forbindelser som adenosin-A1-receptorantagonister
DK2285765T3 (da) Fremgangsmåde til fremstilling af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre
UY32460A (es) Derivados de ciclopropilamida '983"
CL2010001639A1 (es) Proceso para preparacion del hemitartrato de [5-(4,6-dimetil-1h-benzoimidazol-2-il-metil-pirimidin-2-il]-[3-(metil-piperidin-4-il)propil]amina; proceso de recristalizacion del hemitartrato; y hemitaatrato cristalino de [5-(4,6-dimetil-1h-benzoimidazol-2-il)-4-metil- pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina.
AR060442A1 (es) Derivados cristalinos de (2-oxo-1,2,4,5-tetrahidro-1,3-benzodiazepin-3-il)piperidina
WO2012143874A1 (en) A process for the preparation of morpholino sulfonyl indole derivatives
EA200870038A1 (ru) Способ получения аминов
EA201270421A1 (ru) 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт
AR078179A1 (es) Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
GT200500224A (es) Proceso para la sìntesis de indoles n-alquilados c-2, c-3 sustituidos ùtiles como inhibidores de cpla2

Legal Events

Date Code Title Description
FB Suspension of granting procedure